Cart
sales@molnova.com
Tyrphostin B44, (+) enantiomer
CAS No. 133550-37-5
Tyrphostin B44, (+) enantiomer( —— )
Catalog No. M23490 CAS No. 133550-37-5
Tyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 0.86 μM and has less active than the (-) enantiomer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 79 | In Stock |
|
| 5MG | 71 | In Stock |
|
| 10MG | 111 | In Stock |
|
| 25MG | 193 | In Stock |
|
| 50MG | 259 | In Stock |
|
| 100MG | 372 | In Stock |
|
| 200MG | 505 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTyrphostin B44, (+) enantiomer
-
NoteResearch use only, not for human use.
-
Brief DescriptionTyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 0.86 μM and has less active than the (-) enantiomer.
-
DescriptionTyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 0.86 μM and has less active than the (-) enantiomer.
-
In Vitro(+)-Tyrphostin B44 (Tyrphostin AG 835) (Compound B50) (0-100 μM) inhibits cell survival with EC50 values of 3.12, 12.5 and 12.5 μM against CALO, INBL and HeLa cells, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number133550-37-5
-
Formula Weight308.33
-
Molecular FormulaC18H16N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (324.33 mM)
-
SMILESC[C@@H](c1ccccc1)NC(/C(/C#N)=C/c(cc1)cc(O)c1O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
-
Lapatinib ditosylate...
Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
-
LDC4297
LDC4297 is a potent and selective CDK7 inhibitor.
